Patents by Inventor Katharina Fleischauer

Katharina Fleischauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for stimulating CTLs with peptides
    Patent number: 6353089
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These “T-RAS” bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: July 7, 1999
    Date of Patent: March 5, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Thierry Boon-Falleur, Catia Traversari, Katharina Fleischauer
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 6019987
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: February 1, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre Van Der Bruggen, Thierry Boon-Falleur, Catia Traversari, Katharina Fleischauer
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 5554506
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: September 10, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pierre van der Bruggen, Thierry Boon-Falleur, Catia Traversari, Katharina Fleischauer